Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Reports $5.8 Million in Q2 Cash Payments

NEW YORK, July 1 - CombiMatrix generated $5.8 million in cash payments for the second quarter, the company's parent, Acacia Research, said today.

 

CombiMatrix has a semiconductor-based microarray technology, which it is marketing and using to develop siRNA compounds that target common viral diseases.

 

The Squolamie, Wash., company did not specify the source of CombiMatrix's revenues, but CombiMatrix CEO Amit Kumar did mention the company's collaboration with Roche, its strategic alliance with Toppan, and the launch of the siRNA drug discovery program, Express Track.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.